Recent advances in the development of subunit-based RSV vaccines.
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections causing pneumonia and bronchiolitis in infants. RSV also causes serious illness in elderly populations, immunocompromised patients and individuals with pulmonary or cardiac problems. The significant morbidity and mortality associated with RSV infection have prompted interest in RSV vaccine development. In the 1960s, a formalin-inactivated vaccine trial failed to protect children, and indeed enhanced pathology when naturally infected later with RSV. Hence, an alternative approach to traditional killed virus vaccines, which can induce protective immunity without serious adverse events, is desired. Several strategies have been explored in attempts to produce effective vaccine candidates including gene-based and subunit vaccines. Subunit-based vaccine approaches have shown promising efficacy in animal studies and several have reached clinical trials. The current stage of development of subunit-based vaccines against RSV is reviewed in this article.
a School of Chemistry and Molecular Biosciences , The University of Queensland , St Lucia , Queensland , Australia.
Noushin
N
Jaberolansar
a School of Chemistry and Molecular Biosciences , The University of Queensland , St Lucia , Queensland , Australia.|b Institute for Molecular Bioscience , The University of Queensland , St Lucia , Queensland , Australia.|c School of Pharmacy , The University of Queensland , Woolloongabba , Queensland , Australia.
Istvan
I
Toth
a School of Chemistry and Molecular Biosciences , The University of Queensland , St Lucia , Queensland , Australia.|b Institute for Molecular Bioscience , The University of Queensland , St Lucia , Queensland , Australia.|d Australian Infectious Diseases Research Centre , The University of Queensland , St Lucia , Queensland , Australia.
Paul R
PR
Young
a School of Chemistry and Molecular Biosciences , The University of Queensland , St Lucia , Queensland , Australia.
Mariusz
M
Skwarczynski
D000818:Animals; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000639:trends; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000276:immunology* / Q000302:isolation & purification; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology / Q000302:isolation & purification
D022261:Respiratory Syncytial Virus Vaccines; D022223:Vaccines, Subunit
Nanoparticles; RSV; respiratory syncytial virus; subunit vaccine; virus-like particles